In the few years since its first release in 2011, Genedata Biologics® has been rapidly adopted by the majority of the world’s leading biopharmaceutical companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and roll out and deployment support.
Janssen, Celgene, and Aptevo discuss why they chose Genedata Biologics to accelerate their biotherapeutics R&D processes and how the platform’s structured database gives them immediate and central access to all information along the workflow so they can make better informed decisions. They also describe how they use the platform to mine the data, look at trends, and implement machine learning strategies to gain critical business intelligence.
Here is a sampling of companies that rely on Genedata Biologics for their large-molecule discovery activities.
Bayer Pharma AG, one of the world's leading global specialty pharmaceutical companies, licensed Genedata Biologics® as the backbone of their Biologics Data Platform (BDP). The BDP supports biologics data management and analysis at Bayer Pharma R&D sites worldwide, where they are developing novel protein-based therapeutics for diseases such as cancer, hemophilia, and multiple sclerosis. The platform provides shared data storage and data exchange to synchronize Bayer Pharma’s activities from biologics screening all the way through to production. Developed for both antibody-based and other protein therapeutics, the platform supports key tasks such as library generation, laboratory logistics, biologics registration, and analytics. It directly interacts with laboratory equipment, including screening robots, and integrates into Bayer Pharma’s existing IT infrastructure.
Boehringer Ingelheim chose Genedata Biologics® as their global biologics R&D workflow and data management platform. The Genedata Biologics platform supports multiple Boehringer Ingelheim R&D groups in the US and Europe, including Lead Identification and Screening, Lead Optimization and Engineering, and Protein Production groups across Boehringer Ingelheim’s New Biological Entities (NBEs) centers. Genedata Biologics streamlines biopharma discovery operations by integrating workflows and data from diverse research processes and antibody discovery platforms, such as phage and yeast display, hybridomas, and B-cells, as well as downstream expression, purification, and analytics.
GSK Biopharm R&D selected Genedata Biologics® as their key R&D data management and workflow-support platform. The Genedata Biologics platform supports multiple GSK Biopharm R&D groups spanning lead identification and screening, protein optimization and engineering, and protein production. The system records, manages, and processes data from GSK’s diverse antibody discovery platforms such as phage and yeast display, hybridoma, and other technologies, including proprietary ones. In addition, Genedata Biologics helps to improve data quality, increase efficiency through automated upload and export of instrument data, raise experimental throughput, and streamline workflows. Genedata supports the deployment and roll-out of the Genedata Biologics system, its integration into GSK’s R&D environment, and its use of GSK’s high-throughput automation platforms. Genedata and GSK are working together to support new discovery technologies and next-generation antibody formats such as GSK’s domain antibodies and other proprietary molecules and technologies.
Merck Serono, the biopharma business of Merck, Darmstadt, Germany, has adopted Genedata Biologics® as their central workflow platform at biopharma R&D units in Germany, Israel, and the US, where the company is called EMD Serono. Using Genedata Biologics, Merck Serono is streamlining its large-molecule research processes to increase both productivity and quality. The platform addresses Merck Serono’s proprietary workflows and technologies, such as their high-throughput B-cell screening platform, as well as protein engineering workflows for next-generation antibody formats, and novel library technologies. The system is being deployed across different biopharma research centers and is harmonizing all biologics discovery processes, including molecular biology, expression, purification, and analytics processes. It is fully integrated into Merck Serono’s IT landscape and laboratory infrastructure.
Pfizer Inc. licensed the Genedata Biologics® enterprise platform for use at Pfizer biopharma research and development sites in the U.S. and Europe. Genedata is supporting Pfizer’s global deployment and roll out project at Pfizer’s Global Biotherapeutic Technologies (GBT), Centers for Therapeutic Innovation (CTI), and Pharmaceutical Sciences groups. The platform is used for antibody discovery and protein engineering and supports, in one integrated system, the full diversity of Pfizer’s large-molecule processes and technologies.
Sanofi, a leading global healthcare company, has chosen Genedata Biologics® as its data management platform for biologics screening activities. The first-in-class enterprise system is used across different Sanofi research sites as a data management and workflow support platform to automate experimental data capture, increase experimental throughput, and facilitate data sharing throughout the biologics R&D process. The platform enables fully automated, high-throughput biopharmaceutical discovery and development workflows and directly interacts with laboratory instruments and robotics equipment. By increasing experimental throughput, minimizing data handling errors, and ensuring consistently high data quality standards, Genedata Biologics significantly improves efficiency in the discovery and development of novel protein-based therapeutics.
UCB, a global biopharmaceutical company, has licensed Genedata Biologics® to support global biopharma discovery and lead-finding activities in the fields of central nervous system disorders and autoimmune and inflammatory disorders conducted in the UK and Belgium. Genedata Biologics supports novel discovery technologies including all antibody and next-generation protein therapeutics and is used as a central biologics registration and data management platform. The central access to all relevant information on UCB molecules supports UCB’s complex R&D workflows across multiple sites and research groups.
MorphoSys, a pioneer in the field of therapeutic antibodies, uses Genedata Biologics® to support internal and partner-based biologics discovery programs for lead finding and optimization. Genedata Biologics integrates with the MorphoSys laboratory infrastructure and interacts with their discovery technologies, including proprietary antibody libraries, screening, and expression platforms.
F-star, a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products, has licensed Genedata Biologics® to support therapeutic discovery for cancer indications. The platform will be used to increase the throughput of F-star’s proprietary bispecific antibody (mAb² ™) discovery operations from early screening and lead identification, to expression, purification, analytics and manufacturability assessment. Genedata Biologics increases the experimental throughput of F-star’s proprietary technology platform, which is used to introduce a novel antigen-binding site into the constant (Fc) region of an antibody. The resulting molecule (called Fcab™) can rapidly be inserted into any existing antibody to generate a full-length mAb². Genedata Biologics provides an integrated assessment of bioactivity, developability, and manufacturability for all such drug candidates.
Crescendo Biologics, a biopharmaceutical company discovering and developing potent, highly differentiated mono- and multi-specific Humabody® therapeutics in oncology, has implemented Genedata Biologics® as their backbone workflow platform to increase throughput and efficiency in their immuno-oncology and next-generation ADC R&D programs. Genedata Biologics enables a high throughput, systematic approach to the identification of novel therapeutic candidates, allowing for simultaneous optimization of both bioactivity and biophysical parameters. Crescendo will use the software to facilitate swift identification and tracking of potential drug candidates with superior potency and developability.
Kymab Ltd., a leading biopharmaceutical group focused on the discovery and development of fully human monoclonal antibody drugs, has licensed Genedata Biologics® for use in their proprietary antibody discovery programs. The platform will support biopharma R&D operations from early B-cell and hybridoma screening, to antibody engineering, expression, purification, and analytics. Kymab uses Genedata Biologics for their screening platform to deeply mine the proprietary KymouseTM antibody repertoire and to identify candidate-quality molecules with exceptionally broad diversity and the quality of fully human antibodies.